long intergenic non-protein coding RNA 2667Genealiases: []
Q-omics provides the consensus-scored LINC02667 profile across patient tissues and cancer cell-line models. LINC02667 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC02667 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, LINC02667 RNA expression shows 8,895 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight COAD, and KIRC as cancer lineages where LINC02667 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02667 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02667 survival associations across molecular data types. LINC02667 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02667 RNA expression–survival associations across cancer types. High LINC02667 expression shows unfavorable associations in COAD, BLCA, LUAD and UCEC, but favorable associations in KIRC and UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC02667 RNA expression.
This table summarizes LINC02667 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02667. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02667 shows lower tumor expression in KIRC, BRCA, HNSC, KICH and KIRP and higher tumor expression in THCA. The KIRC box plot shows higher LINC02667 RNA expression in normal versus tumor tissue (log2 FC = −0.085, t-test p = .003).
This table shows molecular features associated with LINC02667 in patient tissues and cancer cell lines. In patient samples, LINC02667 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
